Literature DB >> 19591933

UBE3A/E6-AP regulates cell proliferation by promoting proteasomal degradation of p27.

Amit Mishra1, Swetha K Godavarthi, Nihar Ranjan Jana.   

Abstract

The UBE3A/E6-AP is known to function both as an E3 ubiquitin ligase of the ubiquitin proteasome system and as a transcriptional coactivator. E6-AP shows brain-specific imprinting and loss of function of maternally inherited E6-AP causes Angelman syndrome. However, how the loss of function of E6-AP causes disease pathogenesis is poorly understood. Here, we show that E6-AP interacts with and promotes proteasome-mediated degradation of cyclin-dependent kinase inhibitor p27. E6-AP also directly ubiquitinates p27 in an in vitro ubiquitination assay. Partial knockdown of E6-AP increases the level of p27 leading to cell cycle arrest. Interestingly, partial knockdown also increases the transcription of p27. Finally, we have demonstrated the increased levels of p27 in E6-AP-maternal-deficient and null mice brain. Our result suggests that E6-AP not only enhances the degradation but also regulates the expression of p27 and its loss of function in Angelman syndrome might cause cell cycle alteration leading to disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591933     DOI: 10.1016/j.nbd.2009.06.010

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  41 in total

Review 1.  Long non-coding RNAs and cancer: a new frontier of translational research?

Authors:  R Spizzo; M I Almeida; A Colombatti; G A Calin
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 2.  Misfolded proteins recognition strategies of E3 ubiquitin ligases and neurodegenerative diseases.

Authors:  Deepak Chhangani; Nihar Ranjan Jana; Amit Mishra
Journal:  Mol Neurobiol       Date:  2012-09-22       Impact factor: 5.590

3.  KIAA0317 regulates pulmonary inflammation through SOCS2 degradation.

Authors:  Travis B Lear; Alison C McKelvey; John W Evankovich; Shristi Rajbhandari; Tiffany A Coon; Sarah R Dunn; James D Londino; Bryan J McVerry; Yingze Zhang; Eleanor Valenzi; Christine L Burton; Rachael Gordon; Sebastien Gingras; Karina C Lockwood; Michael J Jurczak; Robert Lafyatis; Mark J Shlomchik; Yuan Liu; Bill B Chen
Journal:  JCI Insight       Date:  2019-10-03

4.  Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.

Authors:  Twishi Gulati; Cheng Huang; Franco Caramia; Dinesh Raghu; Piotr J Paul; Robert J A Goode; Simon P Keam; Scott G Williams; Sue Haupt; Oded Kleifeld; Ralf B Schittenhelm; Cristina Gamell; Ygal Haupt
Journal:  Mol Cell Proteomics       Date:  2018-02-20       Impact factor: 5.911

5.  E6AP in the brain: one protein, dual function, multiple diseases.

Authors:  Jimmy El Hokayem; Zafar Nawaz
Journal:  Mol Neurobiol       Date:  2013-10-05       Impact factor: 5.590

6.  Implications of RNG140 (caprin2)-mediated translational regulation in eye lens differentiation.

Authors:  Kaori Nakazawa; Yuichi Shichino; Shintaro Iwasaki; Nobuyuki Shiina
Journal:  J Biol Chem       Date:  2020-08-23       Impact factor: 5.157

Review 7.  The function of p27 KIP1 during tumor development.

Authors:  Jinhwa Lee; Sung Soo Kim
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

8.  Ube3a, the E3 ubiquitin ligase causing Angelman syndrome and linked to autism, regulates protein homeostasis through the proteasomal shuttle Rpn10.

Authors:  So Young Lee; Juanma Ramirez; Maribel Franco; Benoît Lectez; Monika Gonzalez; Rosa Barrio; Ugo Mayor
Journal:  Cell Mol Life Sci       Date:  2013-12-01       Impact factor: 9.261

Review 9.  Protein quality control system in neurodegeneration: a healing company hard to beat but failure is fatal.

Authors:  Deepak Chhangani; Amit Mishra
Journal:  Mol Neurobiol       Date:  2013-02-03       Impact factor: 5.590

Review 10.  Angelman syndrome - insights into a rare neurogenetic disorder.

Authors:  Karin Buiting; Charles Williams; Bernhard Horsthemke
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.